XML 27 R16.htm IDEA: XBRL DOCUMENT v3.25.3
STOCK-BASED COMPENSATION
 9 Months Ended
Sep. 30, 2025
Share-Based Payment Arrangement [Abstract]  
STOCK-BASED COMPENSATION

NOTE 10. STOCK-BASED COMPENSATION

 

The Company recorded pre-tax compensation expense related to the grant of stock options and restricted stock issued of $32,450 and $101,467 for the nine months ended September 30, 2025 and 2024, respectively.

 

As of September 30, 2025, the Company had adopted ten separate stock option and restricted stock plans: (i) the 2005 Stock Option and Restricted Stock Plan (the “2005 Plan”), (ii) the 2006 Stock Option and Restricted Stock Plan (the “2006 Plan”), (iii) the 2007 Stock Option and Restricted Stock Plan (the “2007 Plan”), (iv) the 2008 Stock Option and Restricted Stock Plan (the “2008 Plan”), (v) the 2011 Stock Option and Restricted Stock Plan (the “2011 Plan”), (vi) the 2013 Stock Option and Restricted Stock Plan (the “2013 Plan”), (vii) the 2015 Stock Option and Restricted Stock Plan (the “2015 Plan”), (viii) the 2018 Stock Option and Restricted Stock Plan (the “2018 Plan”), (ix) the 2020 Stock Option and Restricted Stock Plan (the “2020 Plan”), and (x) the 2022 Stock Option and Restricted Stock Plan (the “2022 Plan”). The 2005 Plan, 2006 Plan, 2007 Plan, 2008 Plan, 2011 Plan, 2013 Plan, 2015 Plan, 2018 Plan, 2020 Plan and 2022 Plan are referred to as the “Plans.”

 

Stock option grants. The Company believes that such awards better align the interests of our employees with those of its stockholders. Option awards have been granted with an exercise price equal to the market price of its stock at the date of grant with such option awards generally vesting based on the completion of continuous service and having ten-year contractual terms. These option awards typically provide for accelerated vesting if there is a change in control (as defined in the Plans). The Company has registered all shares of Common Stock that are issuable under its Plans with the SEC. A total of 69 shares remained available for awards under the various Plans as of September 30, 2024.

 

The fair value of each option award is estimated on the date of grant using a Black-Scholes option valuation model.

 

Activity in the various Plans during the nine months ended September 30, 2025 and 2024 is reflected in the following table:

  

Options  Number of
Shares		  

Weighted

Average
Exercise Price

 
Outstanding at January 1, 2025   26   $102,907.69 
Granted   —    — 
Exercised   —    — 
Forfeited   —    — 
Outstanding at September 30, 2025   26   $102,907.69 
Exercisable at September 30, 2025   26   $102,907.69 

 

Options  Number of
Shares		  

Weighted

Average
Exercise Price

 
Outstanding at January 1, 2024   27   $91,100.00 
Granted   —    — 
Exercised   —    — 
Forfeited   (1)   — 
Outstanding at September 30, 2024   26   $91,100.00 
Exercisable at September 30, 2024   26   $91,100.00 

 

 

The fair value of each option award is estimated on the date of grant using a Black-Scholes option valuation model

 

The Plans allow for the cashless exercise of stock options. This provision allows the option holder to surrender/cancel options with an intrinsic value equivalent to the purchase/exercise price of other options exercised. There were no shares surrendered pursuant to cashless exercises during the nine months ended September 30, 2025 and 2024.

 

At September 30, 2025 and December 31, 2024, the aggregate intrinsic value of options outstanding was approximately $-0- and $-0-, respectively, and the aggregate intrinsic value of options exercisable was approximately $-0- and $-0-, respectively.

 

The following table summarizes the range of exercise prices and weighted average remaining contractual life for outstanding and exercisable options under the Company’s option plans as of September 30, 2025:

 

   Outstanding options   Weighted average   Exercisable options   Weighted average 
Exercise price
range		  Number of
options		   remaining
contractual life		   Number of
options		   remaining
contractual life		 
                 
$0.01 to $39.999   1    6.3 years    1    6.3 years 
$40,000 to $69,999   7    5.8 years    7    5.8 years 
$70,000 to $99,999   10    4.1 years    10    4.1 years 
$100,000 to $129,999   7    2.9 years    7    2.9 years 
$130,000 to $159,999   1    0.6 years    1    0.6 years 
                     
Total   26    4.1 years    26    4.1 years 

 

Restricted stock grants. The Board of Directors has granted restricted stock awards under the Plans. Restricted stock awards are valued on the date of grant and have no purchase price for the recipient. Restricted stock awards typically vest over one to four years corresponding to the anniversaries of the grant date. Under the Plans, unvested shares of restricted stock awards may be forfeited upon the termination of service to or employment with the Company, depending upon the circumstances of termination. Except for restrictions placed on the transferability of restricted stock, holders of unvested restricted stock have full stockholder’s rights, including voting rights and the right to receive cash dividends.

 

A summary of all restricted stock activity under the equity compensation plans for the nine months ended September 30, 2025 and 2024 is as follows:

 

   Number of
Restricted
shares		  

Weighted

average
grant date
fair value

 
Nonvested balance, January 1, 2025   25   $10,960.00 
Granted   —    — 
Vested   (12)   (7,060.00)
Forfeited   —    — 
Nonvested balance, September 30, 2025   13   $9,082.31 

 

    Number of
Restricted
shares		    

Weighted

average
grant date
fair value

  
Nonvested balance, January 1, 2024     27     $ 22,540.00  
Granted     40       4,240.00  
Vested     (16 )     (20,120.00 )
Forfeited     (26 )     (44,400.00 )
Nonvested balance, September 30, 2024     25     $ 8,680.00  

 

The Company estimated the fair market value of these restricted stock grants based on the closing market price on the date of the grant. As of September 30, 2025, there was $26,084 representing total unrecognized compensation costs related to all remaining non-vested restricted stock grants, which will be amortized over the next thirty-one months in accordance with their respective vesting scale.

 

The nonvested balance of restricted stock vests as follows:

 

Years ended  Number of
shares		 
     
2025 (October 1, 2025 to December 31, 2025)   — 
2026   6 
2027   4 
2028   3 
2029   —